Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
Martin SchulerLisa ZimmerKevin B KimJeffrey A SosmanPaolo Antonio AsciertoMichael A PostowFilip Y F L De VosCarla M L van HerpenMatteo S CarlinoDouglas B JohnsonCarola BerkingMicaela B ReddyAllison S HarneyJordan D BerlinRodabe N AmariaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ribociclib + binimetinib can be safely administered and is clinically active in patients with NRAS-mutant melanoma. Co-mutations of cell-cycle genes may define a population with greater likelihood of treatment benefit. See related commentary by Moschos, p. 2977.